City Therapeutics (NASDAQ:CTY) Stock Price Down 5% – Here’s What Happened

City Therapeutics, Inc. (NASDAQ:CTY) dropped 5% during mid-day trading on Wednesday. The company traded as low as $18.09 and last traded at $18.63. Approximately 345,963 shares traded hands during mid-day trading, an increase of 27% from the average daily volume of 272,810 shares. The stock had previously closed at $19.62.

Trending Headlines about City Therapeutics

These are some of the CTY headlines that stood out recently:

• Positive Sentiment: City dosed the first participant in a Phase 1 trial of CITY-RBP4, its RNAi candidate for Stargardt disease. The program targets RBP4 and is the company’s second to enter clinical development, adding a potential catalyst to its pipeline. Company announcement
• Positive Sentiment: New analyst coverage was broadly bullish: Oppenheimer rated CTY “outperform” with a $46 target, while Jefferies and Stifel initiated “buy” ratings with targets of $32 and $34, respectively. Those targets indicate analysts see substantial potential from the cited share price, though they depend on the company’s early-stage programs succeeding. Oppenheimer ratings Jefferies ratings Stifel ratings
• Neutral Sentiment: Short-interest reports conflict: one lists 822,840 shares short as of October 30, while another reports zero as of November 10. The discrepancy makes the latest short-interest picture unclear; the October figure was about 1.6% of shares, with 2.3 days to cover.

Analysts Set New Price Targets

A number of research firms recently weighed in on CTY. The Goldman Sachs Group began coverage on shares of City Therapeutics in a research note on Tuesday. They set an “early-stage biotech” rating on the stock. Stifel Nicolaus started coverage on City Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $34.00 price target for the company. Oppenheimer began coverage on City Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $46.00 price objective on the stock. Jefferies Financial Group started coverage on City Therapeutics in a research note on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. Finally, Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Three investment analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, City Therapeutics currently has an average rating of “Buy” and an average price target of $37.33.

City Therapeutics Stock Performance

Insider Buying and Selling at City Therapeutics

In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the stock in a transaction on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the transaction, the insider directly owned 13,692,507 shares of the company’s stock, valued at $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Nelsen acquired 170,000 shares of the company’s stock in a transaction on Monday, October 19th. The stock was acquired at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the completion of the purchase, the director directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

City Therapeutics Company Profile

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.